Carcinoma, Non-Small-Cell Lung

"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Descriptor ID	D002289
MeSH Number(s)	C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
Concept/Terms	Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Carcinoma, Non Small Cell Lung Carcinomas, Non-Small-Cell Lung Lung Carcinoma, Non-Small-Cell Lung Carcinomas, Non-Small-Cell Non-Small-Cell Lung Carcinomas Nonsmall Cell Lung Cancer Non-Small-Cell Lung Carcinoma Non Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Thoracic Neoplasms [C04.588.894]
Respiratory Tract Neoplasms [C04.588.894.797]
Lung Neoplasms [C04.588.894.797.520]
Bronchial Neoplasms [C04.588.894.797.520.109]
Carcinoma, Bronchogenic [C04.588.894.797.520.109.220]
Carcinoma, Non-Small-Cell Lung [C04.588.894.797.520.109.220.249]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Neoplasms [C08.381.540]
Carcinoma, Bronchogenic [C08.381.540.140]
Carcinoma, Non-Small-Cell Lung [C08.381.540.140.500]
Respiratory Tract Neoplasms [C08.785]
Lung Neoplasms [C08.785.520]
Bronchial Neoplasms [C08.785.520.100]
Carcinoma, Bronchogenic [C08.785.520.100.220]
Carcinoma, Non-Small-Cell Lung [C08.785.520.100.220.500]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Non-Small-Cell Lung".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.

Bar chart showing 1841 publications over 31 distinct years, with a maximum of 115 publications in 2013 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	9	1	10
1992	11	1	12
1993	11	3	14
1994	16	3	19
1995	18	1	19
1996	20	5	25
1997	16	7	23
1998	18	4	22
1999	25	9	34
2000	41	9	50
2001	28	7	35
2002	34	5	39
2003	46	6	52
2004	54	7	61
2005	57	9	66
2006	56	11	67
2007	66	8	74
2008	70	8	78
2009	73	5	78
2010	71	12	83
2011	96	6	102
2012	91	14	105
2013	107	8	115
2014	90	7	97
2015	97	10	107
2016	93	8	101
2017	92	9	101
2018	104	11	115
2019	94	10	104
2020	30	2	32
2021	0	1	1

Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.

Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021 01; 27(1):152-164.

View in: PubMed
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601.

View in: PubMed
Ochieng JK, Kundu ST, Bajaj R, Leticia Rodriguez B, Fradette JJ, Gibbons DL. MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs. Oncogene. 2020 10; 39(43):6719-6732.

View in: PubMed
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 09 24; 383(13):1207-1217.

View in: PubMed
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824.

View in: PubMed
Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 11; 31(11):1536-1544.

View in: PubMed
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 11; 31(11):1491-1505.

View in: PubMed
Shannon VR. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer. Curr Opin Pulm Med. 2020 07; 26(4):326-340.

View in: PubMed
Shen X, Zhao Y, Liu G, Zhou HL, Fan J, Zhang L, Li YL, Wang Y, Liang J, Xu ZX. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. Life Sci. 2020 Sep 01; 256:117923.

View in: PubMed
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.

View in: PubMed

People

Explore

Similar Concepts

Top Journals